The strange case of Canada’s Ebola vaccine became even stranger Monday.
That’s when the pharmaceutical multinational Merck announced it will pay $50 million for commercial rights to manufacture and develop the vaccine, invented at the federal government’s National Microbiological Laboratory in Winnipeg.
That a drug giant would shell out $50 million is not in itself peculiar. At a time when the rich world is close to panicking over Ebola, there are only two experimental vaccines aimed at the virus. Canada’s VSV-EBOV is one of them.
Europe and America have belatedly come to realize that Ebola is not just an African disease.